Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
10.1182/blood-2012-03-415307
Saved in:
Main Authors: | Cortes, J., Lipton, J.H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.-C., Craig, A.R., Michallet, M., Nicolini, F.E., Kantarjian, H. |
---|---|
Other Authors: | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE |
Format: | Article |
Published: |
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/128647 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
by: Nicolini, F.E., et al.
Published: (2016) -
CML treatment in Asia-Pacific region
by: Saengsuree Jootar
Published: (2018) -
Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population
by: Budi Suprapti, et al.
Published: (2020) -
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results
by: Amy D. Shapiro, et al.
Published: (2020) -
Switching from subcutaneous to sublingual immunotherapy during the maintenance phase in patients with house dust mite allergy
by: Kiatiwat P.
Published: (2023)